(MENAFN- GlobeNewsWire - Nasdaq) The global anti-obesity drugs market presents significant growth opportunities due to rising obesity rates and consumer demand for effective treatments. Increasing drug approvals and technological advancements are expanding treatment options. Stakeholder investments and North America's market dominance further drive growth prospects.

Dublin, Oct. 15, 2025 (GLOBE NEWSWIRE) -- The "Anti-Obesity Drugs Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Molecule, Active Compound Used, Mechanism of Action, Type of Agonist, Action Pathway, Route of Administration, Geographical Regions, Sales Forecast and Key Players" report has been added to ResearchAndMarkets's offering.

The global anti-obesity drugs market is estimated to grow from USD 19.6 billion in 2025 to USD 104.9 billion by 2035, representing a CAGR of 18.3% during the forecast period.

The urgent need to address obesity epidemic globally has resulted in the boost of the anti-obesity drugs market. Factors such as increasing obesity prevalence, rising disposable incomes, and greater access to healthcare services are propelling this trend. The recent years have witnessed a rise in the approval of anti-obesity drugs, thereby expanding treatment options for patients. This is a result of the alarming statistics of approximately 40% of adults in the U.S. being classified as obese, with a body mass index (BMI) of 30 or higher.

The anti-obesity drugs target weight loss by regulating appetite, fat absorption, and metabolic processes. These drugs include various therapeutic options designed to assist individuals in managing obesity and related conditions. As global obesity rates increase and the awareness of associated health risks, including diabetes, cardiovascular diseases, and certain cancers rise, the need for effective anti-obesity medications has escalated. It is worth mentioning that, in the recent years, many new anti-obesity drugs have gained regulatory approval, expanding options for patients and offering alternatives to surgical procedures for weight loss.

Anti-obesity medications are vital in enhancing weight loss results, especially for patients with severe obesity-related health issues. Further, these drugs contribute to improved quality of life and can lower healthcare expenses by preventing complications related to obesity. Innovations in drug formulation and delivery systems, along with the integration of novel compounds, have resulted in the development of safer and more effective anti-obesity medications. The growing emphasis on personalized medicine and pharmacogenomics further enhances the potential for tailored treatments that address individual patient needs. Additionally, the rise in telehealth services and digital therapeutics applications is facilitating better patient engagement and adherence to treatment plans.

Public and private sectors are actively providing investments in order to conduct research and development in the anti-obesity space, along with fostering innovation and developing cutting-edge therapies. As the focus on obesity as a chronic disease that needs long-term management increases, the anti-obesity drugs market is poised for substantial growth, presenting significant opportunities for stakeholders in the coming years.

Anti-Obesity Drugs Market: Key Insights

The report delves into the current state of the anti-obesity drugs market and identifies potential growth opportunities within the industry.

Some key findings from the report include:

• Currently, close to 225 drugs are marketed / being developed for the management of obesity; around 50% of these can be administered through the oral route.
• Around 55% of the anti-obesity drugs are presently in their clinical stage of development; of these, majority of these drugs are being evaluated as monotherapy.

• A sizeable proportion (70%) of big pharma players have entered into various partnerships in order to expand their anti-obesity drug portfolios; majority of these partnerships (~30%) were research and development agreements.
• The growing awareness among patients about the health risks associated with obesity coupled with its increasing prevalence, is driving the anti-obesity market and positioning it for steady growth in the foreseeable future.

• The anti-obesity drugs market is anticipated to grow at an annualized rate (CAGR) of 18.3%, till 2035; North America is expected to capture the majority share (~60%) of the market by 2035.
• Currently, the centrally acting anti-obesity drugs dominate the market; notably, parenteral route of administration is expected to capture the majority share (~85%) in the market by 2035.

Anti-Obesity Drugs Market: Key Segments

Small Molecules is the Fastest Growing Segment of the Anti-obesity Drugs Market

In terms of type of molecule, the anti-obesity drugs market is segmented into different type of molecules, such as biologics and small molecules. The majority (54%) of the market share is captured small molecules owing to their proven efficacy, ease of administration, lower production costs, accessibility and established safe drug profiles. However, the landscape is expected to change as biologics emerge as a promising and more effective alternative for the underlying biological pathways associated with obesity.

Semaglutide is Likely to Hold the Largest Share of the Anti-obesity Drugs Market During the Forecast Period

In terms of type of molecule, the anti-obesity drugs market is segmented into various active compounds used, such as semaglutide, retatrutide, survodutide, cagrilintide, orforglipron, liraglutide and other active compounds. Owing to its strong efficacy in weight management and diabetes control, majority of the anti-obesity drugs market is currently captured by semaglutide. However, as research progresses, tirzepatide is gaining attention for its dual action as both a GLP-1 and GIP receptor agonist, demonstrating superior weight loss results in clinical trials. This innovative approach targets various metabolic pathways, offering a more comprehensive treatment for obesity. With its potential for greater efficacy and improved patient outcomes, tirzepatide is expected to rise in prominence, ultimately securing the largest market share in the years to come.

Anti-Obesity Drugs Market for GLP-1 Agonist is Likely to grow at a Relatively Faster Pace During the Forecast Period

In terms of mechanism of action, the anti-obesity drugs / weight loss drugs market is segmented into GLP-1 agonist / GIP agonist, GLP-1 agonist / GCGR agonist, GLP-1 agonist, GLP-1 agonist / amylin analogue, GLP-1 / GCGR / GIP agonist and other mechanisms of action. The current market is dominated by GLP-1 market segment. This is attributed to their well-established mechanism of action, which improve glycemic control, thereby promoting significant weight loss. Their ability to enhance satiety and reduce appetite is the foundation in obesity treatment. However, dual GLP-1 and GIP agonists are anticipated to grow at a comparatively higher CAGR because of their ability to target multiple metabolic pathways. Clinical studies suggest that dual agonists can yield greater weight loss and improved metabolic profiles compared to GLP-1 agonists alone.

Anti-Obesity Drugs Market for Single Agonist is Likely to Grow at a Higher CAGR During the Forecast Period

The market is segmented into different types of agonists, including single-agonist, dual-agonist and tri-agonist. Owing to the ease of use in order to facilitate patient adherence, the single agonist segment currently captures the maximum anti-obesity drugs market share (68%). These medications have a long-standing history of clinical success, which enables healthcare providers to confidently prescribe them based on extensive data. Following it, the dual agonist segment will capture a prominent market share, driven by its capability to address the complexities of obesity by targeting multiple physiological mechanisms simultaneously. This allows for more tailored treatments that can adapt to individual patient needs and conditions. Dual agonists are set to become more popular as healthcare shifts toward personalized medicine, thus resulting in greater investments in their development.

Anti-Obesity Drugs Catering to Centrally Acting Pathways is Likely to Dominate the Anti-Obesity Drugs Market During the Forecast Period

The market caters to a variety of action pathways, including centrally acting, peripherally acting and centrally and peripherally acting pathways. Centrally acting segment currently captures the highest anti-obesity drugs market share (86%) and is expected to dominate the market during the forecast period. This is a result of its effectiveness in modulating appetite and energy expenditure through direct interactions with the central nervous system. Additionally, centrally acting agents have a well-established safety profile, which further solidifies their position in clinical practice. Further, the reliance on centrally acting pathways is likely to remain strong, as they provide a comprehensive approach to managing weight. Despite ongoing research into alternative pathways, robust clinical evidence supporting the efficacy of centrally acting agents ensures their continued dominance in the market. Consequently, while new treatments may emerge, the trend towards centrally acting pathways is expected to persist, reflecting their fundamental role in obesity management.

Currently, Parenteral Route Hold the Largest Share of the Anti-Obesity Drugs Market

In terms of route of administration, the anti-obesity drugs market is segmented across oral and parenteral routes. Our research suggests that parenteral route captures the majority share (98%) in the market owing to its rapid onset of action and higher bioavailability compared to oral formulations. Parenteral delivery ensures the medications to bypass the gastrointestinal tract, reducing variability in absorption and enhancing therapeutic effectiveness. It is advantageous for agents that require precise dosing and consistent plasma levels to achieve optimal weight loss outcomes. Moreover, the growing preference for injectable formulations reinforces the trend toward parenteral administration. Consequently, although oral options remain available, the dominance of parenteral administration in the anti-obesity landscape is likely to persist well into the future as well.

North America Accounts for the Largest Share of the Market

The global market value is segmented across various geographies, including North America, Europe, Asia-Pacific, and Latin America. According to projections, North America region accounts for the major anti-obesity drugs market share (70%), which is likely to remain the same during the forecast period. This is complemented by the availability of advanced healthcare infrastructure, significant investment in pharmaceutical research, and robust regulatory frameworks in this region that facilitate the development and approval of new therapies. It is worth highlighting that the market for anti-obesity drugs in Asia-Pacific is expected to grow at a relatively higher CAGR (~40%), till 2035.

Anti-Obesity Market: Research Coverage

• Market Sizing and Opportunity Analysis: The report features a thorough analysis of the global anti-obesity drugs market, in terms of the key market segments, including type of molecule, active compound used, mechanism of action, type of agonist, action pathway, route of administration and geographical regions.
• Market Landscape: An in-depth assessment of the companies involved in anti-obesity market, based on several relevant parameters, such as including status of development, type of molecule, mechanism of action, type of agonist, route of administration, dosage frequency and type of therapy.
• Company Competitiveness Analysis: A comprehensive competitive analysis of ant-obesity drugs, examining factors, such as company strength and pipeline portfolio.
• Company Profiles: Detailed profiles of key service providers engaged in the anti-obesity drugs market, focused on overview of the company, financial information, pipeline portfolio, and recent developments and an informed future outlook.
• Big Pharma Initiatives A review of the various anti-obesity initiatives undertaken by big pharma players, highlighting trends across various parameters number of initiatives, year of initiative, type of initiative, type of partnership and type of expansion.

Key Players in the Antibody Contract Manufacturing Market Profiled in the Report Include

• Boehringer Ingelheim
• Eli Lilly
• Novo Nordisk
• Other Drug Developers
• Eli Lilly
• Pfizer
• Regeneron
• Kallyope
• CinFina Pharma
• Viking Therapeutics
• AstraZeneca
• Novo Nordisk
• Roche
• Adocia
• Boehringer Ingelheim
• Zealand Pharma
• Hanmi Pharm
• Jiangsu Hengrui Pharmaceuticals
• Gmax Biopharma
• PegBio
• QL Biopharm
• Sciwind Biosciences

Key Questions Answered in this Report

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What factors are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

Additional Benefits

• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

Report Segmentation

Type of Molecule

• Biologics
• Small Molecules

Active Compound Used

• Tirzepatide
• Semaglutide
• Retatrutide
• Survodutide
• Cagrilintide and Semaglutide
• Orforglipron
• Liraglutide
• Other Active Compounds

Mechanism of Action

• GLP-1 Agonist / GIP Agonist
• GLP-1 Agonist / GCGR Agonist
• GLP-1 Agonist
• GLP-1 Agonist / Amylin Analogue
• GLP-1 / GCGR / GIP Agonist
• Other Mechanisms of Action

Type of Agonist

• Single-Agonist
• Dual-Agonist
• Tri-Agonist

Action Pathway

• Centrally Acting
• Peripherally Acting
• Centrally Acting and Peripherally Acting

Route of Administration

• Oral
• Parenteral

Geographical Regions

• North America
• Europe
• Asia
• Latin America
• Middle East and North Africa

Sales Forecast of Drugs

• Contrave / Mysimba
• Feisumei
• Imcivree
• LOMAIRA
• QSYMIA
• Saxenda
• Wegovy / Ozempic
• Zepbound / Mounjaro
• BI 456906
• CagriSema
• HM11260C
• HRS-9531
• IBI362
• LM-008
• LY3437943
• LY3502970
• TG103
• Semaglutide 7.2 mg (Subcutaneous)
• Semaglutide (Oral)
• XW003

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachments

• Anti Obesity Drugs
• Big Pharma Initiatives

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN15102025004107003653ID1110201011